Stratum Nutrition (St. Louis), a Novus International Inc. business, has been recognized with Nutrition Business Journal’s Business Achievement Award in the Investment in the Future category.
Stratum Nutrition (St. Louis), a Novus International Inc. business, has been recognized with Nutrition Business Journal’s Business Achievement Award in the Investment in the Future category.
The award recognizes the company for business investments that have resulted in successful market expansion, including the Novus acquisition of IQF Group, a Spanish producer of natural carotenoid pigments, which expands Stratum's European market presence; an equity investment in ESM Technologies, makers of Natural Eggshell Membrane and Eggshell Calcium, to form a joint venture; and a technology partnership with KitoZyme of Belgium to advance the science, global sales, and marketing of Artinia, a fiber-based ingredient that supports healthy arteries and overall cardiovascular health.
The award also recognizes the company's expanding R&D efforts, for recently establishing a new, dedicated R&D facility designed to advance dietary supplement and food applications development near its headquarters in Missouri, as well as initiated development of R&D labs in Spain.
Finally, Stratum was also recognized for its partnership with Vitamin Angels on a new humanitarian program Thrive to Five that supplies children with zinc in order to relieve severe diarrhea, as well as the expanding Novus Scholar Programs, which award scholarships to support the research and work of students and professors.
"We are honored to receive this esteemed recognition from Nutrition Business Journal and will continue our efforts to bring ingredient technologies with solid intellectual property and strong scientific and clinical research to market to meet the growing global need for nutrition and health," stated Jeremy Moore, global business director, Stratum Nutrition.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.